Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance

Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25-60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in over- or under-treatment in many cases. With increasing screen-detected DCIS in these years, the nature of DCIS has aroused worldwide attention. A deeper understanding of the biological nature of DCIS and the molecular journey of the DCIS-IDC transition is crucial for more effective clinical management. Here, we reviewed the key signaling pathways in breast cancer that may contribute to DCIS initiation and progression. We also explored the molecular features of…

• NN
  National Natural Science Foundation of China

  Award: 82172344
• MS
  Medical Science and Technology Project of Zhejiang Province

  Award: 2022RC174
• NS
  Natural Science Foundation of Zhejiang Province

  Award: LY21H160039
• SA
  Science and Technology Program of Zhejiang Province